Group items tagged

The functionality of the NeuroImaging Tools and Resources Collaboratory (NITRC) has enabled three distinct components to flourish: Resources Registry (NITRC-R): a collaboratory enabling the distribution, enhancement, and adoption of neuroimaging tools and resources. Image Repository (NITRC-IR): a curated repository of free neuroimaging datasets meeting global standards. Computational Environment (NITRC-CE): a freely downloadable or pay-as-you-go virtual computing cloud-based platform that is pre-configured with popular neuroimaging tools. NITRC-R has become the major web-based collaborative environment enabling the distribution, enhancement, and adoption of neuroinformatics resources. It currently hosts more than 1,000 tools and resources in areas such as magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, positron emission tomography/single-photon emission computed tomography (PET/SPECT), electroencephalography/magnetoencephalography/electrocorticography (EEG/MEG/ECoG), computational neuroscience, and imaging genomics. Since NITRC's inception, there have been more than 10 million total downloads of tools from NITRC-R.

This Funding Opportunity Announcement (FOA) invites applications proposing to conduct research involving pragmatic clinical trials into improving the effectiveness of treatment strategies for comorbid conditions that occur frequently in combination with Alzheimers disease and Alzheimer's disease-related dementias (AD/ADRD).

This Funding Opportunity Announcement (FOA) invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD. Outcomes of this research may suggest novel opportunities for translational research to allow development of individualized, optimized treatment based on circadian phase and amplitude.

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision-making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. Also listed under R01& R03

Since 1998, ADDF has provided more than $29 million in funding for early stage clinical drug trials for Alzheimer's disease and related dementias. To help propel novel drugs into the clinic, ADDF also has provided over $6.5 million in support of final preclinical studies required by regulatory agencies for the initiation of clinical research studies. The goal of the foundation's PACT program is to increase the number of innovative treatments tested in humans for Alzheimer's disease and related dementias. To that end, the program will fund clinical trials through Phase 2a of novel drug candidates, including small molecules and biologics (antibodies, oligonucleotides, peptides, gene therapies, cell therapies); proof-of-concept biomarker-based trials in patients for repurposed/repositioned drugs; and regulatory studies for investigational new drug (IND)/clinical trial application preclinical packages that are required before testing novel drugs in human subjects. Proposed molecular targets will be evaluated based on the strength of available evidence linking the target to the disease and demonstrating that modulating its biological activity will improve symptoms or modify disease progression. Current target areas of interest include but are not limited to neuroprotection, inflammation, vascular function, mitochondria and metabolic function, proteostasis, ApoE, epigenetics, and synaptic activity and neurotransmitters.

Clinical trials for Alzheimer's disease and related dementias have been hindered, in part, by the limited number of biomarkers available to (1) accurately diagnose these diseases, (2) enrich and stratify patient cohorts, (3) demonstrate target engagement for novel therapeutics, and (4) reliably monitor disease progression and response to treatment. While currently available biomarkers have helped to accelerate clinical trials, most are either expensive, invasive, or both, and provide information on a small number of disease targets. Thus, additional biomarkers are needed to provide a more complete picture of the disease.

The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2016 update to the National Plan to Address Alzheimer's Disease.

The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.

This FOA invites applications on novel studies of the molecular mechanisms underlying metformins effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights and better understanding of metformins effects on aging and aging-related diseases.

This FOA invites applications on novel studies of the molecular mechanisms underlying metformin's effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights on and better understanding of metformin's effects on aging and aging-related diseases.

The purpose of this program is to provide continued support to Transition Scholars who have successfully matriculated through the NIH Stimulating Access to Research in Residency (StARR) R38 program as resident investigators, and who demonstrate potential and continued interest in pursuing careers as clinician-investigators. Awards will provide 12-24 months of mentored research and career development support to those individuals who completed R38 research training, have secured a clinical fellowship or early-career faculty appointment (as instructor or assistant professor for less than 40 months at the time of submission or resubmission), and propose a strong research and career development plan towards continued, successful research careers.

This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOAs companion for basic experimental studies with humans.

The Prevention of Lower Urinary tract Symptoms (PLUS) Research Consortium will use qualitative and quantitative strategies to conduct collaborative, transdisciplinary studies to establish the scientific basis for future intervention studies to promote bladder health and prevent lower urinary tract symptoms (LUTS) and associated bladder conditions such as bladder infections, urinary incontinence, voiding dysfunction, overactive bladder and interstitial cystitis/bladder pain syndrome in adolescent and adult women across the life course. This FOA is to invite applications for Clinical Research Centers to build on foundational work to establish a longitudinal cohort study with the intent of identifying plausible targets for future intervention studies. The consortium will also conduct a range of additional studies to facilitate the success of future intervention and implementation studies.

The National Institute on Aging (NIA) invites applications specific to infrastructure that will support, under a single cooperative agreement (U24), phenotypic data harmonization on subjects with Alzheimer's Disease Sequencing Project (ADSP) genetic and genomic data. These data will become a long-lived legacy data set that will be perpetually curated. The FOA will fund a single vanguard network of researchers with expertise in genetics, epidemiology, and clinical specialties who will work with the ADSP and with study cohort leads on data harmonization efforts to optimize the ability to identify well- targeted therapeutic approaches for Alzheimer's disease and related dementias (AD/ADRD).

This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish several mis-folded protein polymorphisms resource networks in the area of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. For the past several years, many studies have developed assays and reagents to understand the biophysical properties of various tau and Aß structural variants such as oligomers, protofibrils, and fibrils. As a result, many imaging, chemical, and immunological tools have been developed to detect different types of Aß and tau polymorphs. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in Aß and tau polymorphs are the long-term goals of the resource networks supported by this FOA.

This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team science strategy and apply high throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements; and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimers disease andrelated dementias (AD/ADRD).

With this solicitation, NIJ seeks proposals for basic or applied research and development projects. An NIJ forensic science research and development grant supports a discrete, specified, circumscribed project that will: (1) increase the body of knowledge to guide and inform forensic science policy and practice, or (2) lead to the production of useful material(s), device(s), system(s), or method(s) that have the potential for forensic application. The intent of this program is to direct the findings of basic scientific research; research and development in broader scientific fields applicable to forensic science; and ongoing forensic science research toward the development of highly-discriminating, accurate, reliable, cost-effective, and rapid methods for the identification, analysis, and interpretation of physical evidence for criminal justice purposes. Projects should address the challenges and needs of the forensic science community. The operational needs discussed at NIJ's FY 2016 Forensic Science TWG meeting may be found on NIJ.gov. Additional research needs of the forensic science community can be found at the Organization of Scientific Area Committees website. While the goals and deliverables of proposed projects do not necessarily need to result in immediate solutions to the posted challenges or needs, they should speak to them and produce knowledge that adds to work towards eventual resolutions.

With this solicitation, NIJ seeks proposals for research and evaluation projects that will: 1. Identify and inform the forensic community of best practices through the evaluation of existing laboratory protocols; and 2. Have a direct and immediate impact on laboratory efficiency and assist in making laboratory policy decisions.

This Funding Opportunity Announcement (FOA) supports concerted efforts that take a multipronged, team-science strategy and apply high-throughput, genome-wide approaches to systematically discover and characterize functional genomic and epigenomic elements and elucidate and validate their functional roles and mechanisms of action underpinning the heterogeneity, pathogenesis, and progression of Alzheimer's disease and related dementias (AD/ADRD).